Pricing and Online Ordering at www.alphalabs.co.uk Pricing and Online Ordering at www.alphalabs.co.uk n freephone order 0800 387732 n buy online at www.alphalabs.co.uk n email order sales@alphalabs.co.uk n freefax order 0800 614249 12 13 Anti-TNFα Therapy Monitoring BioSystems BA200 Analyser Anti-TNFα Therapy Monitoring Quantum Blue® Anti-TNFα Monitoring Product code Description Pack Size LF-TLIF10 Trough level Infliximab 0.4-20 µg/ml 10 tests LF-TLIF25 Trough level Infliximab 0.4-20 µg/ml 25 tests LF-TLAD10 Trough level Adalimumab 1-35 µg/ml 10 tests LF-TLAD25 Trough level Adalimumab 1-35 µg/ml 25 tests LF-ADIF10 Trough level anti-infliximab antibody 10 tests LF-ADIF25 Trough level anti-infliximab antibody 25 tests LF-ADAD10 Trough level anti-adalimumab antibody 10 tests LF-ADAD25 Trough level anti-adalimumab antibody 25 tests BÜHLMANN Laboratories Anti-TNFα drugs provided a major biotherapeutic breakthrough in the treatment of chronic inflammatory conditions and are also used for the treatment of Inflammatory Bowel Diseases when patients do not respond to steroids. These drugs bind TNFα, blocking the action that is responsible for the inflammatory state. However, not all patients undergoing such treatment respond well and among those that do, the level of response can vary between patients and within the same individual over time. The BÜHLMANN Quantum Blue® Therapeutic Drug and Antibody Monitoring Assays (TDM) were the first rapid test to measure trough drug levels in patients’ serum. They allow timely decision making for dose adjustments before the next infusion. Why use Quantum Blue® TDM Assays? n Single use assay - No need to batch samples n Good correlation with ELISA methods n Good linearity across the range n Individually sealed cassette ensures quality n High and low control included in the kit Antibody Testing These drugs can suffer from loss of response due to the development of antibodies against the drug molecules. This can occur in up to 46% of patients (depending on the drug). So, in addition to the importance of determining if the drug level is within the therapeutic window, antibody levels should also be tested. Monitoring patients on treatment is also very important and therefore, anti-drug antibody assays are also available to determine the free antibody level within patients. Following the same format as the drug level assays, the antibody assays will give a qualitative result within an hour enabling immediate adjustment of therapy if required. The BÜHLMANN Quantum Blue Infliximab assay and WHO calibration showed excellent correlation: Keller et al. 2020 Virtual UEGW BioSystems BA200 Analyser The BioSystems BA200 analyser is available either for capital purchase or on a reagent rental basis to run the BÜHLMANN fCAL turbo and fPELA asssays. This bench top instrument offers an excellent alternative to the main stream analysers for faecal testing with comparable performance and efficiency: Key Features n CE marked applications for BÜHLMANN fCAL turbo and fPELA assays n CALEX Cap can be loaded directly onto the analyser n Software is LIM enabled with built in barcode reader for samples and reagents n 200 tests per hour n 88 position free configuration n LED technology n Quick pause (6-24 seconds) to enable loading and unloading of samples and reagents n Chilled rota for reagents and samples n Other assays are available to be used on the instrument Method comparison with the Roche c501 BioSystems BA200 Analyser Product code Description Pack Size 83200 Bench top analyser Each BioSystems
RkJQdWJsaXNoZXIy MTUyODc1Mw==